ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-BTN3A Agonistic Monoclonal Antibody ICT01

Also written as “IPN60340 + azacitidine + venetoclax”, “IV ICT01” and “ICT01”.

Its studies are mostly in Leukemia, Myeloid, Acute · Hematologic Neoplasms, led by Ipsen.

Drug pageAnti-BTN3A Agonistic Monoclonal Antibody ICT01: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since May 28, 20263 company-led studies, 2 open or runningNext primary completion: Oct 15, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ipsen32 open or runningphase 3since May 28, 2026Jan 24, 2020Oct 15, 2027phase 2 · NCT04243499

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 24, 2020First study: phase 2 study in Hematologic NeoplasmsFirst studyNCT04243499 · 293 enrolled · United States, Belgium, France and more
  2. Mar 24, 2022Phase 2 study in Solid Tumor, AdultNCT05307874 · 56 enrolled · France, Germany, United Kingdom
  3. May 28, 2026Phase 3 study in Leukemia, Myeloid, AcutePhase 3 reachedNCT07623187 · 540 planned

Ahead

  1. Oct 15, 2027Primary completion: phase 2 study in Hematologic NeoplasmsNCT04243499
  2. May 31, 2031Primary completion: phase 3 study in Leukemia, Myeloid, AcuteNCT07623187

TargetBeta

BTN3A1 →read by rule
“A humanized agonistic monoclonal antibody directed against butyrophilin subfamily 3 member A (BTN3A; CD277), ”NCIt, by rule

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07623187Leukemia, Myeloid, Acute3Not yet recruitingMay 31, 2031540
NCT05307874Solid Tumor, Adult · France, Germany, United Kingdom2TerminatedOct 9, 202556
NCT04243499Hematologic Neoplasms · United States, Belgium, France and more2Active, not recruitingOct 15, 2027293

How it is read

Names in the registry

  • “IPN60340 + azacitidine + venetoclax”, 1 entry
  • “IV ICT01”, 1 entry
  • “ICT01”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.